TSOI Panoramica delle azioni Therapeutic Solutions International, Inc. Maggiori dettagli
Analisi del rischio + 2 più rischi
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Therapeutic Solutions International, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Therapeutic Solutions International Prezzi storici delle azioni Prezzo attuale dell'azione US$0.0002 Massimo di 52 settimane US$0.0017 Minimo di 52 settimane US$0.0002 Beta 1.51 Variazione di 1 mese -50.00% Variazione a 3 mesi -69.23% Variazione di 1 anno -86.67% Variazione a 3 anni -99.19% Variazione a 5 anni -91.67% Variazione dall'IPO -99.86%
Notizie e aggiornamenti recenti Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 15
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients Mar 05
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene Oct 21 Vedi altri aggiornamenti Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 15
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients Mar 05
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene Oct 21
Res Nova Bio Appoints George Delgado to Scientific Advisory Board Oct 18
Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils Oct 01
Therapeutic Solutions International Appoints Navneet Boddu to Scientific Advisory Board Sep 19
Therapeutic Solutions International, Inc. Announces FlorStilbene™? Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer Aug 22 Allogen Biologics Inc. Successfully Manufactures JadiCell
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™ Jul 21
Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 16
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease Nov 15
Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient Oct 25
Therapeutic Solutions International Identifies Cd103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for Jadicell Mesenchymal Stem Cell Mediated Lung Protection Oct 06 Therapeutic Solutions International, Inc. announced that it expects to receive $10 million in funding from GHS Investments, LLC Sep 21
Therapeutic Solutions International Announces Positive Data and Filing of Patent Covering the Use of Campbellcell for Treatment of Bipolar Disorder by the Company’S Suicide Prevention Based Spin-Off Campbell Neurosciences Sep 20
Therapeutic Solutions International Develops Post Jadicell Maintenance Therapy for Chronic Obstructive Pulmonary Disease Sep 13
Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome Aug 30
Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome Aug 26
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16
Therapeutic Solutions International, Inc. Reports Superior Efficacy of ApoptoCyte™ on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches Aug 13
Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells Jul 29
Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial Jul 19
Therapeutic Solutions International Appoints Donald Banerji to Scientific Advisory Board May 26
Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial May 24 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International Announces New Data Demonstrating Enhancement of Therapeutic Activities of the Jadicell May 13 Therapeutic Solutions International, Inc. Files Investigational New Drug Application May 10
Therapeutic Solutions International, Inc. Announces Launching of Phase III Clinical Trial for Treating Covid-19 Lung Damage Using its Jadicell Universal Donor Stem Cell Drug May 03
Therapeutic Solutions International Identifies Novel Biological Pathway Apr 20
Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model Feb 08
Therapeutic Solutions International Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation Jan 04
Therapeutic Solutions International Successfully Treats No Option Patients with its JadiCell Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial Dec 31
Therapeutic Solutions International, Inc. Receives Patent for Cancer and COVID-19 Treatment Dec 29
Therapeutic Solutions International, Inc. Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in Covid-19 Model Sep 24
Therapeutic Solutions International Successfully Treats Veteran Navy Seal Suffering from Chronic Traumatic Encephalopathy with Jadicell™ Adult Stem Cells Under Right to Try Law Sep 14
Therapeutic Solutions International, Inc. Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer Aug 31
Therapeutic Solutions International, Inc. Announces Positive Preclinical Results Using Jadicells™ in Animal Model of Chronic Obstructive Pulmonary Failure (COPD) Aug 24
Therapeutic Solutions International, Inc. Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Aug 12
Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell™ Chronic Traumatic Encephalopathy (CTE) Clinical Trial Aug 10
Therapeutic Solutions International, Inc. Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell™ Universal Donor COVID-19 Therapy Aug 06
Therapeutic Solutions International, Inc. Spin-Off Campbell Neurosciences Initiates Pilot Implementation of Campbell Score™ with California Concierge Medical & Wellness Inc Jul 03
Therapeutic Solutions International Demonstrates Potent Brain Protective Activity of JadiCells in Animal Model of Post-Covid-19 Neurological Damage Jul 01
Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models Using Low Dose Naltrexone and T Regulatory Cell Stimulation Jun 17
Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC Jun 08
Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model Jun 03
Therapeutic Solutions International, Inc. Announces New Data Demonstrating Synergy Between its Tumor Blood Vessel Killing Vaccine, StemVacs-V iPSC and Specific Immunological Adjuvants May 25
Therapeutic Solutions International, Inc. Develops Novel Stem Cell Based Therapy to Reduce Lung Scarring: Potential Solution to Post COVID-19 Lung Deterioration May 22
Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model May 18
Therapeutic Solutions International, Inc. Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy Apr 27
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Announces Novel Cancer-Resistant iPSC-Derived Dendritic Cell Immunotherapy: StemVacs-V™ Mar 17
Therapeutic Solutions International, Inc. Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention Mar 05
Therapeutic Solutions International Approves on RangeMe to sell QuadraMune™ and NanoStilbene™ Along with Other Supplements Mar 04
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™ Feb 26
Therapeutic Solutions International Uses Stemvacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells Feb 23
Therapeutic Solutions International Appoints Dr. Boris Minev to Scientific Advisory Board Feb 18
Therapeutic Solutions International Reports Preliminary Data Suggesting StemVacs Induces Natural Killer Memory to Cancer Feb 09
Therapeutic Solutions International Enters into Master Sales Agreement with Community Shield LLC Feb 05
Therapeutic Solutions International, Inc. Announces Filing of Patent Disclosing Enhancement of Natural Killer Cell and T Cell Activity by Stemvacs After Treatment with Homotaurine, A Safe Blood-Brain Barrier Permeable Gaba A-R-Specific Agonist Jan 28
Therapeutic Solutions International Reports Regression of Glioma, Lung Cancer and Colorectal Cancer using StemVacs in Animal Models Jan 26
Therapeutic Solutions International Reports Successful Treatment of Breast Cancer Using StemVacs Cellular Immunotherapy Jan 20
Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences Jan 14
Therapeutic Solutions International Reports QuadraMune Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity Jan 06
Therapeutic Solutions International, Inc. Reports QuadraMune Increases T Cell Immunity in Animal Studies Dec 31
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell Dec 19 Therapeutic Solutions International Announces Clinical Trial Assessing "Kaihani Score" Proprietary Biomarker Based Assay for Quantifying Gambling Addiction Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 18
Therapeutic Solutions International, Inc. Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbene Nutraceutical Product Nov 11
Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score Oct 30
Therapeutics Solution International, Inc. Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene Oct 20
Therapeutic Solutions International Appoints Serena Robella as Director of Sales Oct 13 Rendimenti per gli azionisti TSOI US Pharmaceuticals US Mercato 7D -33.3% 0.4% -2.1% 1Y -86.7% 2.2% 21.3%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: TSOI ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 2.2 % nell'ultimo anno.
Rendimento vs Mercato: TSOI ha avuto una performance inferiore al mercato US che ha registrato un rendimento 21.3 % nell'ultimo anno.
Volatilità dei prezzi Is TSOI's price volatile compared to industry and market? TSOI volatility TSOI Average Weekly Movement 37.2% Pharmaceuticals Industry Average Movement 11.0% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di TSOI è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di TSOI è aumentata da 28% a 37% nell'ultimo anno.
Informazioni sull'azienda Therapeutic Solutions International, Inc. si concentra sulla modulazione immunitaria per il trattamento di varie malattie specifiche negli Stati Uniti. L'azienda sviluppa una serie di agenti immuno-modulatori per il trattamento di tumori, schizofrenia, ideazione suicida e lesioni cerebrali traumatiche, oltre che per la salute quotidiana. I suoi prodotti di punta sono QuadraMune, una miscela sinergica brevettata di pterostilbene, sulforafano, epigallocatechingallato e timoquionone per aumentare l'attività delle cellule natural killer e la produzione di citochine sane.
Mostra di più Therapeutic Solutions International, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Therapeutic Solutions International con la sua capitalizzazione di mercato? TSOI statistiche fondamentali Capitalizzazione di mercato US$1.54m Guadagni(TTM ) -US$2.41m Ricavi(TTM ) US$85.32k
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) TSOI Conto economico (TTM ) Ricavi US$85.32k Costo del fatturato US$29.18k Profitto lordo US$56.14k Altre spese US$2.47m Guadagni -US$2.41m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.00047 Margine lordo 65.80% Margine di profitto netto -2,824.94% Rapporto debito/patrimonio netto 49.0%
Come si è comportato TSOI nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/10 07:40 Prezzo dell'azione a fine giornata 2025/01/10 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Therapeutic Solutions International, Inc. è coperta da 0 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
